valeria visconte
valeria visconte
Verified email at
Cited by
Cited by
Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis
H Makishima, V Visconte, H Sakaguchi, AM Jankowska, S Abu Kar, ...
Blood, The Journal of the American Society of Hematology 119 (14), 3203-3210, 2012
Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A
AM Jankowska, H Makishima, RV Tiu, H Szpurka, Y Huang, F Traina, ...
Blood, The Journal of the American Society of Hematology 118 (14), 3932-3941, 2011
Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms
F Traina, V Visconte, P Elson, A Tabarroki, AM Jankowska, E Hasrouni, ...
Leukemia 28 (1), 78-87, 2014
Deficient CD4+ CD25+ FOXP3+ T regulatory cells in acquired aplastic anemia
EE Solomou, K Rezvani, S Mielke, D Malide, K Keyvanfar, V Visconte, ...
Blood, The Journal of the American Society of Hematology 110 (5), 1603-1606, 2007
SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts
V Visconte, H Makishima, A Jankowska, H Szpurka, F Traina, A Jerez, ...
Leukemia 26 (3), 542-545, 2012
Th17 immune responses contribute to the pathophysiology of aplastic anemia
RP de Latour, V Visconte, T Takaku, C Wu, AJ Erie, AK Sarcon, ...
Blood, The Journal of the American Society of Hematology 116 (20), 4175-4184, 2010
SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes
V Visconte, HJ Rogers, J Singh, J Barnard, M Bupathi, F Traina, ...
Blood, The Journal of the American Society of Hematology 120 (16), 3173-3186, 2012
Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes
MA Sekeres, RV Tiu, R Komrokji, J Lancet, AS Advani, M Afable, ...
Blood, The Journal of the American Society of Hematology 120 (25), 4945-4951, 2012
Emerging roles of the spliceosomal machinery in myelodysplastic syndromes and other hematological disorders
V Visconte, H Makishima, JP Maciejewski, RV Tiu
Leukemia 26 (12), 2447-2454, 2012
Urokinase induces basophil chemotaxis through a urokinase receptor epitope that is an endogenous ligand for formyl peptide receptor-like 1 and-like 2
A de Paulis, N Montuori, N Prevete, I Fiorentino, FW Rossi, V Visconte, ...
The Journal of Immunology 173 (9), 5739-5748, 2004
Soluble and cleaved forms of the urokinase-receptor: degradation products or active molecules?
N Montuori, V Visconte, G Rossi, P Ragno
Thrombosis and haemostasis 93 (02), 192-198, 2005
Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic pathogenesis
A Jerez, Y Sugimoto, H Makishima, A Verma, AM Jankowska, ...
Blood, The Journal of the American Society of Hematology 119 (25), 6109-6117, 2012
Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy
RZ Mahfouz, A Jankowska, Q Ebrahem, X Gu, V Visconte, A Tabarroki, ...
Clinical cancer research 19 (4), 938-948, 2013
Involvement of the urokinase-type plasminogen activator receptor in hematopoietic stem cell mobilization
C Selleri, N Montuori, P Ricci, V Visconte, MV Carriero, N Sidenius, ...
Blood 105 (5), 2198-2205, 2005
Single Nucleotide Polymorphism Array Lesions, TET2, DNMT3A, ASXL1 and CBL Mutations Are Present in Systemic Mastocytosis
F Traina, V Visconte, AM Jankowska, H Makishima, CL O’Keefe, P Elson, ...
Public Library of Science 7 (8), e43090, 2012
Rho kinase regulates the survival and transformation of cells bearing oncogenic forms of KIT, FLT3, and BCR-ABL
RS Mali, B Ramdas, P Ma, J Shi, V Munugalavadla, E Sims, L Wei, ...
Cancer cell 20 (3), 357-369, 2011
Genomic determinants of chronic myelomonocytic leukemia
BJ Patel, B Przychodzen, S Thota, T Radivoyevitch, V Visconte, ...
Leukemia 31 (12), 2815-2823, 2017
Pathogenesis of myelodysplastic syndromes: an overview of molecular and non-molecular aspects of the disease
V Visconte, RV Tiu, HJ Rogers
Blood research 49 (4), 216, 2014
T-cell immune responses to Wilms tumor 1 protein in myelodysplasia responsive to immunosuppressive therapy
EM Sloand, JJ Melenhorst, ZCG Tucker, L Pfannes, JM Brenchley, A Yong, ...
Blood, The Journal of the American Society of Hematology 117 (9), 2691-2699, 2011
Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic leukemia but largely absent in juvenile myelomonocytic leukemia
SA Kar, A Jankowska, H Makishima, V Visconte, A Jerez, Y Sugimoto, ...
Haematologica 98 (1), 107, 2013
The system can't perform the operation now. Try again later.
Articles 1–20